You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. MDCT Quantification of hepatic tumor viability for assessment of cancer therapy

    SBC: IQ MEDICAL IMAGING LLC            Topic: 102

    Project SummaryAbstract Tumor imaging quantification is critical for diagnosisstagingand treatment evaluationand multi detector CTMDCTis the clinical imaging modality commonly used for patients diagnosed with hepatic malignancy because of its relatively low cost and wide availabilityConventional tumor quantification using either linear or volumetric measurement has demonstrated significant limitat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation

    SBC: Cellerant Therapeutics, Inc.            Topic: NIAID

    PROJECT SUMMARY State of the art techniques result inyear solid organ graft loss ofto overin cardiopulmonary organ transplantationEstablishment of donor specific immunological toleranceDSITa condition in which a recipient accepts a transplant without immunosuppressionwhile retaining the ability to fight infectionswould reduce graft loss and transplant related complicationsThe only identified metho ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease

    SBC: ASTROCYTE PHARMACEUTICALS INC.            Topic: NIA

    PROJECT SUMMARY Alzheimerandapos s diseaseADis an area of significant unmet need that creates a national burden of$billion annuallyAD is the leading cause of dementiaaffectingof Americans over the age ofDemographic shifts and the age related nature of AD will soon place this disease as the costliest health care expenditure in the U Swith a projected impact of $trillion per year byCurrent therapies ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosisIPFthe most common of the interstitial lung diseasesoccurs in aboutpeoplewithnew cases diagnosed annually in the USThe typical clinical course is a progressive fibrotic disease characterized by scarring and `honeycombingandaposof the lungs causing an irreversible loss of the tissueandapos s ability to transport oxygenCo morbid pulmonary hypertension is commonly seen in ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

    SBC: THERATARGET, INC.            Topic: 102

    SUMMARY This STTR Phase II proposal addresses the significant need for improved treatment options for patients with liver cancerthe fifth highest incidence of cancer in the worldBecause of the lack of symptomshepatocellular carcinomaHCCis detected at advanced stages inof casesfor which theyear survival rate isand atyears it isThe only curative option for advanced HCC is surgical liver resection an ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers

    SBC: PROTEIN METRICS INC            Topic: 400

    Project SummaryGlycosylation is one of the most prevalent and important post translational modifications of proteinsyet it is also one of the most difficult to studyNo single method nor analytical platform can give complete information about the glycosylation in a protein sampleand the analytical methods in current use include both ESI and MALDI single and tandem mass spectrometryat least four typ ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. The nGoggle: A portable brain-based device for assessment of visual function deficits

    SBC: NGOGGLE INC            Topic: N

    PROJECT SUMMARY Assessment of loss of visual function outside the foveal area is an essential component of the management of numerous conditionsincluding glaucomaretinal and neurological disordersDespite the significant progress achieved with the development of standard automated perimetrySAPmany decades agoassessment of visual field loss with SAP still has significant drawbacksSAP testing is limi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. O-Glycan-dependent Immunotherapy for Cancer

    SBC: GLYTR THERAPEUTICS, INC.            Topic: 102

    Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Pirenzepine for CIPN

    SBC: WinSanTor, Inc.            Topic: NCI

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government